Casey Kopczynski - Aerie Pharmaceuticals Insider

0P0 -- Germany Stock  

EUR 62.78  0.59  0.93%

  Founder
Dr. Casey C. Kopczynski, Ph.D., is Chief Scientific Officer and CoFounder at Aerie Pharmaceuticals, Inc. From 2002 to 2005, he was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. He was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002
Age: 54  Founder Since 2005  Ph.D    
919-237-5300  http://www.aeriepharma.com
Kopczynski received his PhD in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.

Management Efficiency

The company has return on total asset (ROA) of (32.66) % which means that it has lost $32.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (99.89) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 123.92 M in total debt with debt to equity ratio (D/E) of 52.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals has Current Ratio of 13.3 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Entity Summary

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. Aerie Pharmaceuticals operates under Drug Manufacturers - Major classification in Germany and traded on Frankfurt Stock Exchange. It employs 160 people.Aerie Pharmaceuticals (0P0) is traded on Frankfurt Stock Exchange in Germany. It is located in 4301 Emperor Boulevard and employs 160 people.

Aerie Pharmaceuticals Leadership Team

Vicente Anido, Chairman of the Board, CEO
Julie McHugh, Independent Director
Murray Goldberg, Board Member
Richard Lewis, Chief Medical Officer
John LaRocca, General Counsel
Benjamin McGraw, Independent Director
Casey Kopczynski, Co-Founder, Chief Scientific Officer
Richard Rubino, CFO
Anand Mehra, Director
Gerald Cagle, Director
Thomas Mitro, President COO
Richard Croarkin, Director
Michael Toit, Independent Director
Eric Carlson, Vice President - Research & Development
Tori Arens, Vice President - Drug Product Manufacturing
Geoffrey Duyk, Director
Deanne Melloy, Vice President - Marketing

Stock Performance Indicators

Current Sentiment - 0P0

Aerie Pharmaceuticals Investor Sentiment
Macroaxis portfolio users are unresponsive in their sentiment towards investing in Aerie Pharmaceuticals. What is your sentiment towards investing in Aerie Pharmaceuticals? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Thematic Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Thematic Ideas
Explore Investing Ideas  
Check also Trending Equities. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">